Genentech, a member of the Roche Group, announced the FDA approved the Vabysmo (faricimab-svoa) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet, or neovascular, AMD, diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). The Vabysmo PFS will become available to US retina specialists and their patients in the coming months, the company said in a press release.

According to the company, Vabysmo PFS delivers the same medicine as the currently available Vabysmo vials in an alternative, ready-to-use format. Vabysmo will continue to be available in a 6.0 mg vial.

Vabysmo is the first and only bispecific antibody approved for the eye and has demonstrated rapid and robust vision improvements and retinal drying in wet AMD, DME and RVO, the company said.